Lorlatinib: First Global Approval

  title={Lorlatinib: First Global Approval},
  author={Yahiya Y. Syed},
Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Based on results from a phase I/II trial, lorlatinib received approval in Japan in September 2018 and in the USA in November 2018 for the treatment of ALK-positive NSCLC. This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this… 

Lorlatinib as a treatment for ALK-positive lung cancer.

Pivotal clinical trials are discussed along with the current status of lorlatinib as a treatment for ALK-positive lung cancer and future therapeutic challenges.

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Entrectinib has been well studied across many tumor types, including NSCLC with ALK, ROS1, and NTRK rearrangements, and the drug has demonstrated favorable properties with oral administration, prolonged response duration, high intracranial efficacy, and a favorable toxicity profile.

Brigatinib as a treatment of ALK-positive non-small cell lung cancer

An up-to-date overview of the current and evolving clinical data regarding the biology of the disease, the emerging clinical decision-making and the targeted therapy options in advanced NSCLC harboring ALK translocation is presented, especially focusing on the activity of brigatinib.

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

Both oral and IV lorlatinib were well-tolerated in healthy participants and oral lorLatinib is highly bioavailable after oral administration.

A user's guide to lorlatinib.

The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer

This drug discovery case history focuses on the key studies that led to the preclinical discovery and development of osimertinib and focuses on published preclinical studies by scientists from AstraZeneca and highlight key events in the clinical development.

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study

Lorlatinib is highly brain penetrant and exhibits autoinduction after multiple dosing, and there appears to be no inherent differences in lorLatinib PK between healthy subjects and cancer patients, or between Asian and non-Asian patients.

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC

This work focuses on anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, as an oncogenic driver in NSCLC, and discusses the available treatment options for ALK-positive NSCLCs with an emphasis on the second-generation ALK inhibitor ceritinib.

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives

This review aims to provide an overview of underlying molecular alterations of ALK-i resistance and point out promising role of liquid biopsy in predicting tumor response and monitoring resistance mutations and to deepen the role of clinicopathological and genomic characteristics influencing patients’ prognosis during treatment with ALk-i.

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

Lorlatinib, a third-generation ALK inhibitor, has demonstrated activity in the treatment naïve setting and in resistance to crizotinib and second- generation ALK inhibitors, which is associated with the development of ALK resistance mutations, specifically G1202R.



Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations

Lorlatinib exhibited antitumor activity across a variety of ALK kinase domain resistance mutations, including the difficult-to-treat ALK G1202R mutation.

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer

Current preclinical and clinical studies are focused on the development of rational therapeutic strategies, including novel ALK inhibitors, as well as rational combination therapies to maximize disease control by delaying or overcoming acquired therapeutic resistance.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain, and sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation.

Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer

The identification of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in ~3–5% of non–small cell lung cancer (NSCLC) tissues and the demonstration that the

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

In vitro kinase assays and cell-based experiments examining ALK mutations of increasing potency show that PF-06463922 is an effective inhibitor of ALK with greater activity towards ALK neuroblastoma mutants.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

The next-generation ALK/ROS1 inhibitor PF-06463922 exerts unparalleled activity in ALK-driven neuroblastoma models with primary crizotinib resistance and exerts unprecedented activity as a single targeted agent against F1174L and F1245C ALk-mutated xenograft tumors, while also inducing responses in an R1275Q Xenograft model.